×
About 6,328 results

ALLMedicine™ Myasthenia Gravis Center

Research & Reviews  2,126 results

Rituximab for Anti-cytokine Autoantibody-Associated Diseases
https://clinicaltrials.gov/ct2/show/NCT01842386

Jun 24th, 2022 - Anticytokine autoantibodies are an important and emerging cause of disease. Anticytokine autoantibody-associated diseases include disseminated nontuberculous mycobacterial infection caused by anti-interferon- >= autoantibodies, severe mucocutaneou...

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT04963270

Jun 24th, 2022 - This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).

Intravenous magnesium sulfate inducing acute respiratory failure in a patient with myas...
https://doi.org/10.1136/bcr-2022-250455
BMJ Case Reports; Jessop K

Jun 24th, 2022 - A woman in her 90s with a background of myasthenia gravis and atrial fibrillation presented to hospital following a fall. While in the emergency department it was noted that she was in atrial fibrillation with a fast-ventricular response and as pa...

Role of complement, anti-complement therapeutics, and other targeted immunotherapies in...
https://doi.org/10.1080/1744666X.2022.2082946
Expert Review of Clinical Immunology; Dalakas MC

Jun 23rd, 2022 - Several patients with myasthenia gravis (MG) do not adequately respond to available drugs or exhibit poor tolerance, necessitating the need for new therapies. The paper discusses the rapidly evolving target-specific immunotherapies that promise lo...

Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT05067348

Jun 22nd, 2022 - This study is a randomized, double-blind, placebo-controlled study, to be conducted at 6 study sites. Approximately 64 subjects will be enrolled. Patients with MG who are positive for anti-AChR antibodies will be enrolled. Patients who do not have...

see more →

Guidelines  4 results

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic synd...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105910
Journal of the Neurological Sciences; , Jacob S et. al.

Apr 5th, 2020 - Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.|2020| ,Jacob S,Muppidi S,Guidon A,Guptill J,|complications,drug therapy,epidemiology,therapeutic use,therapeutic use,t...

The Association of British Neurologists' myasthenia gravis guidelines.
https://doi.org/10.1111/nyas.13503
Annals of the New York Academy of Sciences; Sussman J, Farrugia ME et. al.

Nov 10th, 2017 - Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence-based medicine. Despite the basic principles of treatment being well known, patients continue to recei...

Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critical...
https://doi.org/10.1097/CCM.0000000000002027
Critical Care Medicine; Murray MJ, DeBlock H et. al.

Oct 19th, 2016 - To update the 2002 version of "Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient." A Task Force comprising 17 members of the Society of Critical Medicine with particular expertise in the use of n...

International consensus guidance for management of myasthenia gravis: Executive summary.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977114
Neurology Sanders DB, Wolfe GI et. al.

Jul 1st, 2016 - To develop formal consensus-based guidance for the management of myasthenia gravis (MG). In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international expe...

see more →

Drugs  55 results see all →

Clinicaltrials.gov  158 results

Rituximab for Anti-cytokine Autoantibody-Associated Diseases
https://clinicaltrials.gov/ct2/show/NCT01842386

Jun 24th, 2022 - Anticytokine autoantibodies are an important and emerging cause of disease. Anticytokine autoantibody-associated diseases include disseminated nontuberculous mycobacterial infection caused by anti-interferon- >= autoantibodies, severe mucocutaneou...

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT04963270

Jun 24th, 2022 - This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).

Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT05067348

Jun 22nd, 2022 - This study is a randomized, double-blind, placebo-controlled study, to be conducted at 6 study sites. Approximately 64 subjects will be enrolled. Patients with MG who are positive for anti-AChR antibodies will be enrolled. Patients who do not have...

Acupuncture in Myasthenia Gravis (AcuMG)
https://clinicaltrials.gov/ct2/show/NCT05230082

Jun 21st, 2022 - The purpose of the study is to determine the effect acupuncture treatment on individuals with a diagnosis of Myasthenia Gravis (MG). A total of 20 people with MG will be enrolled in this study to receive acupuncture treatment 2 times a week for 12...

Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT05132569

Jun 21st, 2022 - The duration of the DB period will be 26 weeks. The OLE is up to 104 weeks. The duration of the whole study DB+OLE is 130 weeks.

see more →

News  174 results

Two Investigational Meds Promising for Myasthenia Gravis
https://www.medscape.com/viewarticle/974080

May 16th, 2022 - Two investigational medications are safe and effective for the treatment of generalized myasthenia gravis (gMG), new research shows. The phase 3 studies showed both zilucoplan and rozanolixizumab improve gMG-specific outcomes compared with placebo...

First Human Bird Flu Case in U.S.; Okla. Nears Abortion Ban; Ebola Outbreak in DRC
https://www.medpagetoday.com/infectiousdisease/covid19/98463

Apr 29th, 2022 - Note that some links may require registration or subscription. CDC confirmed the first human case of the H5N1 bird flu in the U.S., in a Colorado man with direct exposure to birds. Oklahoma Gov. Kevin Stitt (R) is expected to sign a "Texas-style" ...

Rapid Rx Quiz: Myasthenia Gravis Treatments
https://www.medscape.com/viewarticle/970022

Mar 15th, 2022 - Myasthenia gravis (MG) is estimated to affect as many as 60,000 patients in the United States and more than 700,000 people worldwide. In approximately 10% of patients, complications can be life-threatening. However, with the right treatment, MG ca...

Rapid Rx Quiz: Myasthenia Gravis Treatments
https://reference.medscape.com/viewarticle/970022

Mar 15th, 2022 - Myasthenia gravis (MG) is estimated to affect as many as 60,000 patients in the United States and more than 700,000 people worldwide. In approximately 10% of patients, complications can be life-threatening. However, with the right treatment, MG ca...

 Muscle-wasting Conditions May be More Common in the UK Than Previous Estimates
https://www.medscape.com/viewarticle/968599

Feb 16th, 2022 - Tens of thousands more people in the UK could be living with neuromuscular disease (NMD) than previous estimates suggested, according to new research. A study in the journal PLOS ONE, which analysed millions of GP records, suggested that the preva...

see more →

Patient Education  14 results see all →